ArticleInfection and drug resistance2022
Deterioration of Cycloserine in Drug Susceptibility Testing of
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes.Infection and drug resistance · 2026Review
- Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.Antimicrobial agents and chemotherapy · 2025Article
- Cycloserine resistance among drug-resistant tuberculosis cases in Taiwan.Microbiology spectrum · 2025Article
- Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems.Beilstein journal of nanotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCycloserine is an effective group C anti-tuberculosis drug. But the reliability and reproducibility of drug susceptibility tests (DST) for this drug cannot be guaranteed and provide poor clinical predictive values. However, DST of cycloserine in practice provides rough estimate of the drug resistance of
methodsThe effectiveness of serial cycloserine solutions incubated at 37°C for 1 to 29 days was tested using the Alamar Blue assay, and cycloserine in culture medium was analyzed by UPLC-MS.
resultsThe data revealed that cycloserine itself continuously degraded in culture medium. This amount of degradation was sufficient to alter the minimum inhibitory concentration (MIC) value of
conclusionThe different test times and the degradation of cycloserine were responsible for the lack of agreements between the cycloserine DST methods and the low reliability of this in vitro test. By adjusting with the incubation time depended degradation ratio of cycloserine, more accurate MIC values may be obtained allowing for improved coincidence between in vitro experiment and clinic use. Furthermore, it can guide clinicians to carry out this anti-tuberculosis treatment more effectively and reliably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.